Bicara Therapeutics BCAX Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -30.9%— | —— | |
| Return on assets | -29.3%-11.0pp | -18.3%— | |
| Return on invested capital | -100.6%— | —— | |
| Liquidity | |||
| Current ratio | 14.6×-13.4× | 27.9×+12.6× | |
| Quick ratio | 14.6×-13.4× | 27.9×+12.6× | |
| Cash ratio | 3.3×-23.9× | 27.2×+11.9× | |
| Leverage | |||
| Debt-to-equity | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | |
| Per Share | |||
| Book value per share | $7.34-74.9% | $29.27+111% | |
| Valuation | |||
| Market capitalization | $921.98M-2.7% | $947.92M— | |
| Enterprise value | $827.01M+80.2% | $458.95M— | |
| Price / book | 2.3×+0.4× | 1.9×— | |
| Free cash flow yield | -11.6%-3.7pp | -7.9%— | |
| Earnings yield | -15%-7.8pp | -7.2%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Bicara Therapeutics's ratios come from?
- Every ratio is computed from Bicara Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.